Status:
COMPLETED
Exparel Use in Adductor Canal Block After Total Knee Arthroplasty
Lead Sponsor:
St. Luke's Hospital, Pennsylvania
Conditions:
Arthritis Knee
Pain, Postoperative
Eligibility:
All Genders
18-99 years
Phase:
PHASE3
Brief Summary
Exparel has been shown to have better pain control compared to previously used infiltration agents, including bupivacaine, while having a minor side effect profile. The purpose of this study is to exp...
Detailed Description
The effectiveness of an Exparel Block (Bupivacaine Liposomal Injectable Suspension) for post-operative pain control has been well studied with encouraging results. At the investigators' institution, E...
Eligibility Criteria
Inclusion
- Patients were eligible for inclusion if they were undergoing unilateral primary TKA for a diagnosis of knee osteoarthritis and were not undergoing any additional concomitant procedures were.
Exclusion
- Patients were not eligible for our study if they were undergoing revision TKA, if they were undergoing bilateral TKA or concomitant procedures, or if they had an active infection.
Key Trial Info
Start Date :
June 1 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 15 2021
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT04910165
Start Date
June 1 2020
End Date
October 15 2021
Last Update
May 20 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
St. Luke's University Health Network
Bethlehem, Pennsylvania, United States, 18015